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Background: Primary immunodeiciency disorders (PIDs) are a group of heterogeneous 
rare disorders, whereby the immune system is missing or not functioning adequately. For 
patients requiring treatment, the most common option is immunoglobulin replacement 
therapy (Ig). Treatment of PIDs is simultaneously associated with both improvements in 
health-related quality of life (HRQoL) and increased treatment burden.
Objectives: This review sought to review studies investigating the burden of Ig treatment, 
synthesize evidence in relation to administration routes (subcutaneous or intravenous) 
and instruments used, as well as make recommendations for clinical and research appli-
cations in this area for patients aged 16 years and older.
methods: We searched Medline, EMBASE, and The Cochrane Library. Sifting of titles 
was performed by two reviewers, and the assessment of full-text articles by three. From a 
database which contained 3,770 unique results, 67 full texts were reviewed. Eventually, 17 
studies were found to meet the inclusion criteria, and included in this review. Due to data 
heterogeneity, a narrative, descriptive synthesis of the evidence was undertaken.
Results: Most studies were carried out in the USA/North America, used a prospective 
observational design and involved patients with common variable immune deiciency. 
Four studies measured the burden of receiving IVIg therapy and 13 measured SCIg 
therapy. A wide range of measures, primarily designed to measure aspects of treatment 
satisfaction (e.g., life quality index or a slightly modiied version) and HRQoL (e.g., The 
Short Form-36) had been used.
conclusion: Lack of a parallel control group in most studies meant that changes in out-
comes could be due to factors other than changes in the treatment regimen. However, 
overall, PID patients appeared to report little Ig treatment burden and were satisied 
with either modality. However, patient preference appeared to be the delivery of the 
Ig treatment in the patient’s home and SCIg was preferred after switching from IVIg 
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therapy. Individual differences appeared to affect treatment preference and therefore 
understanding the decision support needs of PID patients facing IG treatment choices 
would be valuable. Using a questionnaire speciically designed to measure the burden of 
Ig treatment from the patient’s perspective is recommended in future research.
Keywords: systematic review, primary immunodeiciencies, PiD, immunoglobulin treatment, burden of treatment, 
health-related quality of life
iNtRODUctiON
Primary immunodeiciencies (PIDs) are a group of heterogene-
ous rare disorders whereby the immune system is missing or not 
working properly. Consequently, for people living with a PID this 
means that they have a reduced or absent natural defense against 
viruses, bacteria, or fungi and will be susceptible to frequent infec-
tions (1–3), which can have a profound negative impact upon their 
health-related quality of life (HRQoL) (2).
Immunoglobulin replacement therapy (Ig) is the only treat-
ment for most PID patients. It involves undergoing a blood-based 
infusion at regular intervals to raise the antibodies needed to 
ight of infection. It can be administered either intravenously 
or subcutaneously. Although it is generally accepted that Ig 
treatment can dramatically improve HRQoL (2, 4), it may also 
be associated with a substantial treatment burden. Burden of 
treatment (BoT) is a concept which can be deined as the conse-
quences of receiving treatment (these may be medication, thera-
pies, or other interventions). It describes the “work of being a 
patient”—everything the patient needs to do to treat and manage 
their illness, for example, undergoing tests and investigations, 
visiting doctors, adhering to treatment regimens, and making 
lifestyle changes (5, 6).
Intravenous Ig treatment (IVIg) is typically administered in 
hospital and can be infused two, three, or four weekly lasting 
approximately 2–4 h per visit. he precise length of infusion will 
be dependent on dose and tolerance of the individual, although 
the three-weekly interval is most common. Subcutaneous Ig 
treatment (SCIg) is typically administered in the home but can 
be administered in the hospital depending on patients’ individual 
needs. Because it is harder for tissues to accept larger volumes of 
the product quickly via the SC route, it oten means that patients 
will require more frequent infusions of smaller quantities, leading to 
an increased number of injections and localized reactions to needle 
injections (7, 8).
Rationale
While there are numerous studies which have tried to measure the 
HRQoL of patients with a PID [e.g., Ref. (2, 3, 9, 10)], less attention 
has focused upon the burden of Ig treatment. BoT is an important 
concept because it may negatively afect adherence to treatment, 
HRQoL, disease management, and health care outcomes such as 
hospitalizations and survival (5). he outcomes of a 2015 system-
atic review reported that SCIg was associated with better treatment 
satisfaction compared to IVIg and therefore that switching trained 
patients with antibody deiciency from IVIg to SCIg may be advan-
tageous (11).
OBJective aND ReSeaRcH QUeStiON
he purpose of this systematic review was to (i) systematically 
identify studies that measured the burden of Ig treatments 
on the HRQoL of patients with primary immunodeiciencies, 
(ii) appraise and synthesize this evidence in relation to the diferent 
modes of Ig administration available and the instruments used 
and, and (iii) to make recommendations for future clinical and 
research applications in this area.
methods
Study Design
Inclusion Criteria
Included studies had to recruit adults (aged ≥ 16 years) receiving 
immunoglobulin replacement therapy for a PID and report a 
measure of the BoT from the patient’s perspective. Where both 
children and adults were recruited, studies were only included if 
data for adults could be extracted separately from data on chil-
dren (or their parents and the samples were not mixed). Studies 
using HRQoL or treatment satisfaction questionnaires or qualita-
tive assessments of treatment burden were eligible. Studies with 
comparative or non-comparative (e.g., before and ater) designs 
were eligible. Studies were excluded if they reported data from 
the clinician or health service perspective only, were editorials, 
letters, systematic reviews, conference abstracts, or if they were 
published in languages other than English.
Search Strategy: Data Sources
On 18th August 2015, we conducted searches on Medline (includ-
ing Medline in Process), EMBASE, and he Cochrane Library. his 
was subsequently updated on 27th October 2017. Citations were 
imported into EndNote and duplicates deleted prior to scrutiny. 
he searching process aimed to identify studies which reported 
data on the burden of immunoglobulin therapy, from the patient’s 
perspective for primary immunodeiciencies.
he search strategy was developed by an information specialist 
(Mark Clowes) who undertook electronic searching to create a 
database of citations using the EndNote reference management 
system. he search process was recorded in detail with lists of 
databases searched, date search run, limits applied, number of hits, 
and duplication as per PRISMA guidelines (http://www.bmj.com/
content/339/bmj.b2700).
he initial search consisted of terms relating to Ig therapy for 
PID. Due to the large number of diferent types of primary immu-
nodeiciencies with over 250 being identiied as of 2011 (12), it 
was not practical to search for every single type so instead we used 
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a combination of umbrella terms for the major categories and 
speciic terms for some of the most common types.
Further searches were conducted to identify studies 
mea suring:
(i) the quality of life (QoL) of patients living with PID and
(ii) the BoT for those undergoing IGT.
QoL terms were based on a search ilter devised by 
http://nicedsu.org.uk/wp-content/uploads/2016/03/TSD9-
HSUV-values_FINAL.pdf.
BoT terms were based on previous studies: http://www.ncbi.
nlm.nih.gov/pmc/articles/PMC3692487/bin/pmed.1001473.s007.
doc and (6).
he unduplicated searches found a total of 4,002 results. 
Ater de-duplication of results from all the searches, the database 
contained 3,770 unique results. Results were imported in discrete 
sets with labels added to help identify which facet(s) of the topic 
they included. his accelerated the siting process by allowing each 
set of results to be reviewed separately and in accordance with 
appropriate criteria for the topic of the article. No date limits were 
set on any of the searches. However, it was expected that most of 
the evidence would be recent. We did not limit results to English 
language studies but those in other languages were imported and 
screened separately. he MEDLINE search strategy is reported in 
Appendix A1 in Supplementary Material. Similar searches were 
conducted of EMBASE (and EMBASE Classic) and he Cochrane 
Library. Reference lists of relevant papers were also screened and 
citation searches run.
Study Selection and Data Extraction
Initial siting of the search results was performed by one reviewer 
(Georgina L. Jones), and subsequently updated by Katharina 
S. Vogt. Assessment of full-text articles against the inclusion 
criteria was undertaken by three reviewers (Duncan Chambers, 
Katharina S. Vogt, and Georgina L. Jones) and uncertainties 
were resolved by discussion and consensus. Data on study and 
patient characteristics, outcome measures, and study indings 
were extracted from included studies by three reviewers (Duncan 
Chambers, Katharina S. Vogt, and Georgina L. Jones). Data 
extraction forms were developed in advance and tested on a 
small sample of studies prior to the main data extraction process. 
No formal assessment of quality (risk of bias) of the included 
studies was conducted because of the wide range of included 
study types, most of which have no generally accepted tools for 
quality assessment.
Data Synthesis
As this was not an efectiveness review and due to the heterogeneity 
of the data, a narrative and descriptive synthesis of the evidence 
was planned, concentrating on the diferent modes (SC and IV) 
and settings (home and hospital/clinic) available for Ig therapy. A 
meta-analysis would have been conducted had the data allowed for 
this. We also sought to establish the diferent ways in which stud-
ies have characterized and measured the BoT from the patients’ 
perspective, including issues of HRQoL, preference, and inancial 
burden.
ReSULtS
Prisma Flow Diagram
A PRISMA low diagram is presented in Figure 1. Sixty-seven 
full texts were reviewed, of which 17 were included. Publication 
dates ranged between 1991 and 2017. Study characteristics are 
summarized in Table 1 and in more detail in Tables 2 and 3. 
Most studies were carried out in the USA/North America 
(n = 6), Sweden (n = 5), or other European countries (n = 2). 
he remainder involved patients from two or more countries 
(n =  4). Seven studies were prospective observational stud-
ies, mainly reporting changes from baseline (data collection 
ranged from 6 to 24  months), nine reported cross-sectional 
data (questionnaires administered at a single time point although 
one of these was a conjoint analysis study where patients 
expressed preferences for hypothetical treatment regimens 
with diferent features), and there was one crossover rando mized 
trial.
Comparisons were made with the patients’ previous treatment 
and occasionally with a control group (not randomly selected). 
Some studies also compared patients’ HRQoL with that of the 
general population of their country (13) or patients with other 
health conditions. One study looked at the inancial BoT on 
patients in Sweden but these data were published in 1995 (14). 
A US study from 2005 reported on patients’ problems in obtaining 
insurance and access to therapy (15).
Study Selection and Study characteristics
Patient and Treatment Demographics
Most of the patients in the studies had common variable immune 
deiciency (CVID). Other diagnoses included agammaglobulinae-
mia, IgG subclass deiciency, speciic antibody deiciency, selective 
IgA deiciency, and hyper IgM syndromes. Sometimes the speciic 
diagnosis was not included, only PID, or listed as “other.” hree 
studies did not include details of speciic diagnoses. he majority 
of studies (n = 8) looked at BoT in relation to SCIg, the majority 
of which looked at SCIg treatment at home (n = 7). Four stud-
ies looked at IVIg, three were hospital treatment-only, and one 
compared home versus hospital treatment. Five studies compared 
SCIg versus IVIg. One study did not include details of treatment 
route or setting (16).
When the dose of Ig therapy is mentioned, this was at standard 
replacement dose of between 400 and 600  mg/kg/month. Some 
studies used a conversion factor of 1.37 when transferring patients 
from intravenous to subcutaneous treatment. Patients in these stud-
ies were receiving a variety of immunoglobulin brands. he brand 
used will have depended on local preference and availability at the 
time.
Measuring BoT
he studies used a wide range of measures to assess BoT 
(Table  1). hree studies used the life quality index (LQI) or a 
slightly modiied version (13, 17, 18). his is a condition-speciic 
instrument developed speciically to measure IVIg treatment 
satisfaction for patients with a PID. One study used the treatment 
satisfaction questionnaire for medication (TSQM) (13) which is 
FigURe 1 | PRISMA 2009 low diagram.
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a generic instrument that measures a patient’s treatment satisfac-
tion. Other non-validated questionnaires or visual analog scales 
(VASs) developed speciically for the studies had also been used 
to measure BoT. Patient preferences for treatment had also been 
elicited using a conjoint approach in one study (19).
However, most studies (n =  8) used generic HRQoL ques-
tionnaires, the most common being the SF-36 or its short form 
version, the SF-12. he Sickness Impact Proile (SIP) General 
Health Rating Index (GHRI) (20), health opinion survey (HOS), 
and multi-dimensional health locus of control (MHLC) (17, 18, 
21) were also adopted. he preference-based EQ-5D was only 
used in one study (13). Financial BoT was evaluated in two studies 
(15). he table below (Table 1) maps some of the key features of 
the included studies.
What Is the Burden of IVIg Therapy?
Four studies included patients only receiving IVIg therapy 
(15–17, 22).
IVIg Therapy: Home Versus Hospital
Four studies compared patients receiving IVIg at home versus in 
a hospital setting (15–17, 22). One study reported that patients 
receiving home-based treatment (n = 37) had higher LQI scores 
than clinic-based patients. hey reported greater convenience, 
comfort, independence to travel, treatment schedule lexibility, 
and a more pleasant treatment atmosphere. hey also reported 
less disruption of daily activities as well as reduced waiting time 
and treatment-associated travel and cost. Patients who subse-
quently returned to clinic-based therapy had higher LQI scores 
during home-based treatment. No group-diferences were found 
for HOS and MHLC scores. However, the type of PIDs was not 
reported (17).
One study assessed the inancial BoT in 41 US-patients with 
X-linked agammaglobulinemia (15). Overall, patients perceived 
the IV gammaglobulin treatment as burdensome and not the 
condition itself or its symptoms. Reasons for this were the dif-
iculty with scheduling therapy appointments afecting their ability 
taBLe 1 | Summary table of study characteristics.
Study design type of therapy measure of treatment burden
Study Prospective cross-sectional crossover Scig ivig Scig versus ivig QoL Preference, 
satisfaction
Other
Chapel et al. (23) √ √ √
Daly et al. (17) √ √ √ √
Dash et al. (24) √ √ √
Gardulf et al. (26) √ √ √
Gardulf et al. (20) √ √ √
Gardulf et al. (14) √ √ √ √
Gardulf et al. (25) √ √ √ ($)
Gardulf et al. (30) √ √ √
Hansen et al. (27) √ √ √
Howard et al. (15) √ √ √ √ ($)
Jones et al. (13) √ √ √ √
Kittner et al. (28) √ √ √ √
Mohamed et al. (19) √ (conjoint analysis) √ √
Nicolay et al. (18) √ √ √ √
Rider et al (29), √ √ √ √
Routes et al. (16) √ √ √
Tcheurekdjian et al. (22) √ √ √
$: includes data on inancial burden.
QoL, quality of life.
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to travel. However, speciic numbers were not reported and they 
did not distinguish between the two diferent settings where 
treatment was undertaken. hey further reported that almost half 
had experienced diiculty obtaining or maintaining insurance, 
experiences included insurance or coverage denial, conditional 
exclusions, treatment delays, insurance cancelations, or reaching 
their lifetime cap. Finance-related consequences were not receiv-
ing the care they needed; one participant accumulated a $120,000 
hospital bill. Excluding this participant, meant out-of-pocket 
expense for health care was $1,388 (median $500). While it was 
not the aim of the study to directly assess inancial BoT between 
the settings, it was reported in terms of QoL impact: Using the 
SF-12 as a QoL measure, the authors found that treatment setting 
did not signiicantly afect HRQoL (15).
Using the SF-12’s extended version, the SF-36, Tcheurekdjian 
et al. (22) examined diferences between IVIg treatment for CVID 
patients receiving the treatment at home or the clinic. While this 
study did not report their results separately, they did report that 
female gender and older age were associated with lower QoL but 
there was no efect of other variables (including treatment set-
ting) on SF-36 outcomes.
While the heterogeneity makes a comparison of results dii-
cult; overall, it appears as though home-based IVIg was preferable 
to receiving clinic-based treatment, but that treatment setting had 
no signiicant impact upon HRQoL outcomes.
Routes et  al. (16) investigated HRQoL in patients with PID 
before and ater having been on IVIg treatment for 12 months. 
he majority of the sample (88%) received IVIg at a hospital 
rather than at home (12%). As above, HRQoL was assessed using 
the SF-12. Signiicant improvements on patients’ ratings were 
found for physical health, general health, and social function-
ing. While it was also reported that patients had signiicantly 
less emergency room visits associated with their IG treatment, a 
number of patients (n = 12) reported an increase in days missed 
from work or school ater starting their Ig treatment. However, 
this increase was not statistically signiicant.
SCIg Therapy
hirteen studies measured the burden of receiving SC Ig therapy 
(13, 18–20, 23–29). However, none of the included studies 
focused exclusively on hospital or clinic-based therapy.
Gardulf et  al. (25) speciically developed a 38-item question-
naire with eight items on patients’ perception of SCIg treatment; 
four of which concerned patients’ experiences of receiving SCIg 
in general (home and hospital). In a sample of Gothenburg 
patients who had spent a median time of 3  years on treatment, 
the majority were highly satisied with subcutaneous treatment, 
perceived it as efective, and wished to continue. he authors also 
report three observations. First, older patients perceived the SG 
method as more comfortable, but were more anxious to retain the 
treatment. Second, patients who had received a greater number of 
infusions, had lower scores for comfort, and third, women were 
generally more positive relative to men. Out of the 152 patients, 112 
patients had experience of intramuscular and/or intravenous Ig 
treatment. Participants were asked to rank the treatment routes in 
order of preference. One-hundred-and-four patients subsequently 
responded; 96 ranked SC irst, three ranked the intramuscular 
method as their chosen preference and ive ranked IV irst. he 
answers to the open-ended questions were divided into two catego-
ries, positive and negative statements which were further divided 
into sub-themes. Positive answers to the open-ended questions 
were categorized as: a simple and easy method (n = 25), efective 
in preventing infections (n = 23), reduced or no local pain (n = 18), 
and no adverse systemic reactions (n = 10). Negative statements 
were categorized as: time consuming (n = 7), dependent on treat-
ment (n = 6), clumsy method/much equipment needed (n = 4), 
local pain/worry in inserting needles (n = 4), local SC tissue reac-
tions (n = 4), and inefective in preventing infection (n = 3).
taBLe 2 | Study designs and outcome measures used.
Reference Study design Outcome measure
ivig general
Tcheurekdjian  
et al. (22)
Questionnaire 
(cross-sectional)
SF-36
Routes et al. (16) Cohort study (12 months) SF-36
ivig at home
None
Scig at home
Dash et al. (24) Cohort study  
(up to 4 years)
Satisfaction questionnaire
Gardulf et al. (26) Prospective observational 
(12 months)
VAS (0–100)
Gardulf et al. (20) Prospective observational 
(18 months)
67-item questionnaire  
developed for the study,  
SIP, and GHRI
Gardulf et al. (14) Questionnaire 
(cross-sectional)
38-item questionnaire 
developed for the study, 
8 items on perception of 
treatment
Gardulf et al. (30) Questionnaire 
(cross-sectional)
VAS (0–100)
Hansen et al. (27) Prospective observational 
(6 months)
VAS (0–100)
Jones et al. (13) Prospective observational 
(up to 96 weeks)
SF-36, EQ-5D, LQI, TSQM, Ig 
therapy-speciic questionnaire 
Nicolay et al. (18) Prospective observational 
(12 months)
SF-36, LQI
comparative studies
Chapel et al. (23) Crossover randomized 
trial (24 months)
Not applicable (question  
about treatment preference)
Daly et al. (17) Questionnaire 
(cross-sectional)
LQI, comparison scale for 
home versus clinic-based 
treatment, HOS, MHLC
Gardulf et al. (25) Questionnaire 
(cross-sectional)
Cost questionnaire
Howard et al. (15) Questionnaire 
(cross-sectional)
Questionnaire developed 
for the study, quality of life 
measured using SF-12
Kittner et al. (28) Questionnaire 
(cross-sectional)
8-point Likert scales,  
4 scales of FPI
Mohamed et al. (19) Conjoint analysis 12-question conjoint survey 
offering choices between 
hypothetical treatments
Rider et al. (29) Cohort study 
(cross-sectional)
SF-12, IDF survey
EQ-5D, Euroqol-5D; FPI, Freiburg Personality Inventory; GHRI, General Health Rating 
Index; HOS, health opinion survey; IVIg, intravenous immunoglobulin; LQI, life quality 
index; MHLC, multi-dimensional health locus of control scale; SCIg, subcutaneous 
immunoglobulin; SF-36, short form-36; SF-12, short form 12; SIP, sickness impact 
proile; TSQM, treatment satisfaction questionnaire for medication; VAS, visual 
analogue scale.
6
Jones et al. PID and Ig Treatment Burden
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1308
SCIg Therapy at Home
Six of these studies, and thus the majority of them, evaluated SC 
therapy at home only (13, 14, 20, 25–27, 30).
Overall, patients reported a positive experience of receiving 
SCIg at home. In order to assess patients’ perceptions of using SC 
therapy at home, three studies (26, 27, 30) used VASs. Gardulf 
et al. (26) reported that the mean VAS scores for “how do you 
ind the subcutaneous treatment?” were 86 (range 50–99) at 
the start of home treatment and 84 (28–100) ater 12 months. 
For “how determined are you to continue with treatment?” 
scores were 91 (60–100) and 94 (75–100), respectively. For 
corresponding questions about home treatment, mean scores 
were 94 (65–100) and 96 (85–100), respectively. here were no 
signiicant changes over time or requests to change the type or 
place of treatment.
Gardulf et  al. (30), in a study which focused on pregnant 
women and Ig home treatment, found that six of the nine 
women reported no worry about receiving SCIg therapy during 
pregnancy. he other three estimated their worry in early preg-
nancy at 100, 33, and 9 on the VAS scale. Reasons included that 
the baby would feel the needle, how they would receive infusions 
when these could not be given in the abdominal wall, and that 
the dose would not be enough to prevent infection. None of the 
women were worried about receiving treatment at home during 
pregnancy.
Hansen et  al.’s (27) patients perceived local tissue reactions 
to express SCIg infusion (35 ml/h) as less intense or unchanged 
compared with rapid infusion (20 ml/h). Median VAS score for 
local reactions was 16. Patients were positive about the home 
therapy regimen (median VAS at 6 months 96, range 72–100) 
and were keen to continue with express infusions (median VAS 
98, range 73–100). Patients reported that the express regimen had 
made it easier for them to ind time for the therapy (median VAS 
95, range 64–100).
Gardulf et  al. (20, 25) used speciically developed scales in 
their studies, among other measures. First, Gardulf et al. (20) used 
three measures in their study: a 67-item questionnaire, using a 
VAS format that was speciically developed for the study ranging 
from 1 to 100  mm whereby 100 indicated the biggest burden/
problem, the SIP and the GHRI. Over the 18 months from base-
line to follow-up, fears of infections and anxiety about the future 
decreased signiicantly. Patients also reported a signiicantly 
increased ability to participate in recreational activities. For the 
SIP, it was found that patients had signiicantly poorer functional 
status (versus a Swedish reference group) for total SIP score and 
subscales mobility, sleep and rest, household management, work, 
and recreation or pastimes. Ater 18  months, however, difer-
ences were only signiicant for ambulation, mobility, and social 
interaction. For the GHRI, a signiicant improvement in total and 
current health ratings were found at 18 months compared with 
baseline.
Using the remaining four items which speciically asked 
patients about SCIg home therapy, Gardulf et al. (25) found that 
their sample of 115 patients (median time on treatment 2 years 
7 months) from Denmark, Sweden, and Norway receiving SCIg at 
home were overall highly satisied with the treatment and wished 
to continue. Men scored higher than women for perceived control 
of timing of infusions. Identical to the division outlined above, 
answers to the open-ended questions regarding home treatment 
were classiied as positive and negative. he positive statements 
were further categorized as independence/freedom/lexibility 
(n =  57), no travel to hospital (n =  14), less time of work or 
school (n = 4), a sense of being less sick or disabled (n = 3), and 
hospital resources freed for others (n = 3). Stated negatives, or 
taBLe 3 | Clinical characteristics of included studies.
Reference country type of PiD ig treatment 
and place of 
administration
Brand and dose Sample n mean age and 
range
Chapel et al. (23) UK and 
Sweden
CVID 18; IgG subclass deiciency 
10; speciic antibody deiciency 2
SCIg (setting 
unclear); IVIg 
(clinic-based)
SCIg: Gammabulin; IVIg: Endobulin  
(doses 400 mg/kg/month in UK,  
600 mg/kg/month in Sweden)
Adults (>13 years), previously untreated or 
previously on prophylactic Ig therapy
30 44; range 18–67
Daly et al. (17) USA Not reported IVIg (home- or 
hospital-based)
Sandoglobulin (dose not reported) Participants in a trial of home-based IVIg and 
patients treated in a clinic setting at the same 
hospitals
37 
home-
based; 
29 clinic-
based
35.5 (home-
based); 32.5 
(clinic-based)
Dash et al. (24) UK CVID, IgGsubclasss deiciency, 
speciic antibody deiciency,  
IGG heavy chain deiciency
SC (home) Subgam (manufactured by BLP), initial 
weekly dose 100 mg/kg bodyweight—dose 
then individually adjusted
Adults and children enrolled in a trial 
of eficacy and safety of Subgam for 
home-infusion
28 adults 45.5 (21.3–75.2)
Gardulf et al. (26) Sweden Hypogammaglobulinaemia 
(further details not reported)
SCIg (home-based) Gammaglobulin Kabi (100 mg/kg/week) Consecutive patients receiving SCIg by rapid 
infusion at home
25 43; range 18–73
Gardulf et al. (20) Sweden CVID 23; XLA 1; other 1 SCIg (home-based) Brand not reported (100 mg/kg/week) Adults (≥18) with hypogammaglobulinaemia 25 43 (SD 16); range 
18–66
Gardulf et al. (14) Sweden; 
Denmark; 
and 
Norway
Not reported SCIg (home-based) Gammaglobulin Kabi (165 mg/ml); 
Gammabulin (160 mg/ml); and  
Nordimmun (150 mg/ml)
Adults receiving ongoing treatment with SCIg 152 44; range 18–76
Gardulf et al. (25) Sweden CVID or XLA (numbers not 
reported)
SCIg (home-based) Brand not reported (100 mg/kg/week) Adults who switched from hospital to home 
therapy
30 43; range 18–66
Gardulf et al. (30) Sweden cVID 6; IgG subclass deiciency 
2; IgA and IgG2 subclass 
deiciency 1
SCIg (home-based) Gammaglobulin or gammanorm  
(100 mg/kg/week)
Women who became pregnant while 
receiving SCIg at home
9 Mean not reported; 
range 25–43
Hansen et al. (27) Sweden IgG subclass deiciency 29; 
selective IgA deiciency 9;  
CVID 3; XLA 1; others 8
SCIg (home-based) Gammanorm or immunoglobulin  
Baxter (100 mg/kg/week)
Patients who had been on rapid self-infusions 
at home for at least 6 months
50 Median 48; range 
23–74
Howard et al. (15) USA XLA IVIg (home- or 
hospital-based)
Not reported Patients under care of the authors or who 
had participated in previous research studies
41 33; range 21–63
Jones et al. (13) USA CVID SCIg (home-based) Hizentra (dose not reported) Patients from a previous study who agreed to 
enroll in an extension study
21 
enrolled, 
16 
analyzed
47.2 (SD 14.5); 
range 22–69
Kittner et al. (28) Germany CVID 48; IgG subclass deiciency 
1; hyper IgM syndrome 1; XLA 2; 
not stated 9
SCIg (home-based); 
IVIg (hospital-based)
Not reported Patients who had switched to SCIg or opted 
to continue on IVIg
61 (33 
SCIg and 
28 IVIg)
SCIg 37 (SD 9.1); 
IVIg 51.2 (SD 14.5)
Mohamed 
et al. (19)
USA CVID 219; XLA 8; other 25 SCIg or IVIg; home 
or doctor’s ofice, 
hospital, or clinic
Not reported Patients recruited from the Immune 
Deiciency Foundation member panel
252 50.2 (SD 13.8); 
range 19–80
(Continued)
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disadvantages, were time consuming (n  =  23), diiculties in 
storing materials (n = 5), and no skilled help available if needed 
(n = 3).
Jones et al. (13) used a combination of the SF-36, EQ-5D, LQI, 
treatment satisfaction questionnaire for medication (TSQM), and 
an Ig herapy-Speciic Questionnaire. he SF-36 and EQ-5D were 
administered at weeks 1, 24, 48, and 72 and the other measures 
at weeks 1 and 60. It was found that patients’ scores on the SF-36 
scores did not difer signiicantly from US population norms 
except for general health, which was below the population norm. 
he EQ-5D Index Score was stable and within the 95% CI of the 
US population norm. LQI scores ranged from 77.3 to 92.3 across 
visits, indicating that the SCIg treatment had little impact upon 
daily activities. TSQM scores showed high satisfaction following 
treatment. Ig therapy-speciic questionnaire scores relected high 
satisfaction with current therapy and with receiving treatment 
at home.
SCIg: Home Versus Hospital Treatment
One study directly compared the cost associated with subcutane-
ous treatment at home versus at hospital (14). In this study, the 
treatment of 30 patients who were initially receiving hospital-
based SG treatment was switched to home-based therapy. 
Patients completed cost-questionnaires during the initial hospital 
period before starting home therapy, and ater 12 months of being 
on the home-treatment regime. It was found that switching to 
home therapy reduced the mean annual cost to the patients 
from SEK 22,360 to SEK 10,970 (US $2,865 to $1,405). Patients’ 
out-of-pocket expenses (excluding cost of time) fell from SEK 
2,080 to SEK 310 ($265 to $40). Costs of attending the hospital 
for training varied widely between patients. However, overall the 
study concluded that home therapy signiicantly reduces the cost 
associated with SC treatment for patients.
Dash et al. (24) carried out a clinical efectiveness and safety 
trial with a subcutaneous Ig rapid infusion. However, they only 
measured treatment satisfaction and preference in their sample 
with a speciically developed questionnaire. Before the trial-
began, the majority of the sample received IVIg, either at home 
or hospital (n = 22), compared to SCIg (n = 6). At evaluations 
of treatment satisfaction ater 3 and 6-months post-treatment 
began with SCIg, the majority of patients preferred SCIg to their 
previous medication (89% and 76% at 3 and 6-months evalua-
tions, respectively). he authors further report that 56% of their 
sample rated SCIg as more convenient than past treatment and 
36% found it more comfortable.
IVIg Versus SCIg Therapy
Several studies aimed to compare Ig treatment burden in patients 
receiving IVIg or SCIg modalities or in those patients switching 
between these two treatment options.
Chapel et al. (23) investigated patients’ treatment preference in 
the context of an international multicentre study. Five of the UK 
patients preferred the IV route in comparison to four preferring SC. 
Out of the Swedish patients, 11 preferred IV compared to six indi-
cating their preference for SC. Four patients had no preference. 
It is noteworthy that one patient declined to enter the SC phase 
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because of preference for IV therapy and two patients declined to 
switch from SC to IV (preference and fear of virus transmission). 
he preference data include patients who withdrew.
he SF-36 and the LQI was used by Nicolay et al. (18), with 
patients who initially received IV treatment, in home or hos-
pital, but were transferred to received SCIg treatment. Within 
the sample, patients were divided into two sub-groups: patients 
who previously received IV in a hospital setting (group A) 
and patients who received home treatment (group B). Patients 
in group A showed signiicant improvements on the SF-36 
subscales for role-physical, vitality, and general health on all 
three LQI subscales and in satisfaction with route and place of 
treatment. Patients in group B only showed improvements for 
SF-36 general health. Most patients preferred SC administration 
(group A 81%, group B 69%) and treatment at home (group A 
90%, group B 92%).
Finally, two studies contrasting IVIg with SCIg developed 
study-speciic questionnaires (19, 28). Kittner et al.’s (28) study-
speciic questionnaire investigated patients’ attitudes toward 
home-based SCIg therapy, which asked them to answer on an 
8-point Likert scale with values from 1 indicating “not at all” to 8 
indicating “very much.” Four subscales of the Freiburg Personality 
Inventory (FPI) were also administered. Overall, IVIg treated 
patients, who did not want to change to SCIg treatment, were con-
cerned about time required for self-administration (6.9 versus 
3.6) and about severe adverse reactions at home (4.7 versus 1.7). 
On the item “I dislike to puncture myself,” included in the 
study-speciic questionnaire, IVIg patients agreed more strongly 
than SC patients (5.3 versus 2.0). Generally, patients on SCIg 
appreciated their treatment (7.2), and cited increased lexibility 
(50%) as the main advantage. Interestingly, the FPI values were 
lower for SCIg patients for “physical complaints” and “emotional 
lability.”
Mohamed et al. (19) developed a 12-question conjoint survey 
ofering choices between hypothetical treatments. It was found that 
patients preferred home setting, monthly frequency, fewer needle 
sticks, and shorter treatment duration to alternative choices. 
Interestingly, the mode of administration was the least impor-
tant attribute but patients slightly preferred self-administration 
to administration by a health professional. he data for parents of 
children with PID were reported separately and are not reported 
in this review.
Rider et al. (29) used the SF-12 and a study-speciic 75-item 
questionnaire to assess the HRQoL in adult patients with 
PIDs. Out of their sample (n =  945), 55% received IV and 
45% received SC treatment. One question in the study-speciic 
questionnaire assessed the efects of treatment on fatigue, it 
was found that a greater percentage of IV IG patients (46%) 
reported always feeling fatigued or low in energy compared to 
SC patients (29%). In addition, a greater amount of SC patients 
reported “never” to experiencing periods of fatigue or low 
energy compared to IV patients (31 versus 16%). Diferences 
in scores on the SF-12 indicate “modestly” improved scores for 
mental health for SC IG patients compared to IV IG patients. 
Interestingly though, there were no diferences in perceived 
BoT between the administration groups—accessed via the 
study-speciic questionnaire.
DiScUSSiON
Summary of Findings
he aim of this review was to synthesize the evidence in rela-
tion to the burden of Ig therapy as reported from the patient’s 
perspective, and to make recommendations for future clinical 
and research applications. Overall, PID patients reported little 
Ig treatment burden and were satisied with either modality. 
However, patient preference appeared to be the delivery of the 
Ig treatment in the patient’s home and SCIg was preferred ater 
switching from IVIg therapy.
While there was less evidence in relation to IVIg treatment, 
patients receiving this in a home setting were satisied with 
their treatment and wished to continue. Better HRQoL and 
inancial savings, despite some trouble getting insurance cover, 
are recorded to be factors inluencing this preference. Similarly, 
most studies reported high patient satisfaction with SC therapy 
at home and most patients who switched to this regimen pre-
ferred it to their previous treatment (IV hospital–based therapy), 
although one study reported no signiicant diferences in terms of 
preferences about the setting in which SC treatment is received. In 
most studies, switching to SC home therapy was associated with 
improvements in some or all measures of HRQoL. Patients were 
largely positive, satisied, and perceived the therapy as efective, 
giving them greater independence as well as lexibility. Other 
beneits cited included increased lexibility, convenience, and 
self-conidence associated with self-management of the condi-
tion. Aspects perceived as burdensome ater switching to SC 
therapy at home included that it was time consuming, challenging 
to store equipment, and there was a lack of skilled help if needed.
Improvements on HRQoL measures as well as health function-
ing measures were recorded, especially when patients changed 
their treatment to SCIg at home from either IV hospital or IV 
home treatment. From these results, it could be concluded that as 
a result of increasing HRQoL and, potentially decreasing patients’ 
inancial burden, SCIg therapy may be the most cost-efective as 
well as preferred treatment option for PID patients. However, 
more studies investigating the inancial burden of diferent treat-
ment administration routes need to be conducted to fully support 
this claim.
Furthermore, it also important to take factors into account that 
have been reported occasionally in some studies: the importance 
of individual diferences. he choice of which route to use for Ig 
administration depends upon personal preference of the patient, 
ease of intravenous access, dose of Ig required, tolerability of any 
previous Ig products, patient lifestyle, and it can be reviewed 
regularly and adjusted throughout the period of treatment as 
patient’s circumstances change (31). Sometimes choice of product 
may also be limited by speciic country’s insurance and inancial 
arrangements.
Across studies, it was reported that women and men may have 
diferent attitudes and anxieties toward treatment and treatment 
success. In addition, the age of patients may play an important 
role. hose characteristics, as well as some personality traits, 
as measured by Kittner et  al. (28), may signiicantly inluence 
people’s preference and attitudes toward treatment and indings 
like this could be utilized in developing tailored interventions to 
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reduce anxieties of particular groups of PID patients who face Ig 
treatment decisions.
It was surprising to ind that none of the included studies 
in this review were randomized-control trials, but instead had 
adopted cross-sectional designs, which suggests that the area of 
immunoglobulin research for patients with PID requires further 
gold-standard research, especially in connection to HRQoL 
measures and assessment of BoT. However, before this research 
can be conducted, it is important to take account of the following: 
across the 22 studies included in this review, ten diferent “health” 
questionnaires were used (LQI, TSQM, CHQ-50, EQ-5D, FPI, 
SF-36/SF-12, GHRI, SIP, and HOS) (note: this list excludes the 
use of the VAS and other study-speciic measures). his vast 
heterogeneity of diferent measures, subsequently measuring dif-
ferent outcomes does not enable direct comparison across results. 
A new Ig BoT speciic measure is currently in the early stages 
of development and validation, which may be a useful measure 
for standardizing the measurement of Ig treatment burden across 
future studies and as newer Ig therapies and modalities are devel-
oped (32). Two other measures which assess HRQoL have already 
been published and validated, yet were not utilized (33, 34).
While some studies have attempted to gain a more compre-
hensive insight into which factors and characteristics may con-
tribute (e.g., age, gender, and personality factors) and why certain 
treatments may be preferred (e.g., lexibility, freedom to travel, 
frequency of treatment, etc.), the evidence is not yet conclusive. 
Furthermore, data included in this review spans three decades 
from 1987 to October 2017 (when updated). With advances 
in technology as well as shits in the delivery of health care to 
person-centered care, it is possible that people’s understanding, 
demands on and readiness to adapt their treatment regimens may 
have changed. Some of the inancial burden reported may also 
now be out-dated and not applicable anymore as funding rules 
change. Furthermore, many studies emphasizing the superiority 
of SC compared to IV were conducted in single centers, rather 
than across multi-sites. his may have further biased the results 
considering the lack of comparisons that have taken place. It is 
also important to note that with the expansion of rapid infusion 
(IVIg), the length of treatment per  session will have decreased 
and may, therefore, not be more time consuming than SC.
Limitations
here are several limitations of this systematic review. First, in 
regards to the inclusion criteria it was decided to focus on adult 
patients. he age cutof used was 16 years and older because this 
is used in NHS ethics protocols to distinguish between adult and 
pediatric cohorts in the UK. Unfortunately, a few interesting papers 
which were originally thought to have met the inclusion criteria 
were not included in the review because they had classiied the 
adult group as any patient aged 14 years and above and therefore 
this did not meet our inclusion criteria and/or did not report child 
and adult data separately (10, 21, 35–40). One study was excluded 
because ater removing the child cohort data, the data for only 
one adult patient remained, which was deemed insuicient (41). 
However, inclusion or exclusion of the most “marginal” studies 
would be unlikely to afect our overall review indings. hese are 
that any Ig therapy at home was positive including IVIg or SCIg 
but SCIg at home appeared to be associated with less treatment 
burden and was the most desired mode of treatment in patients 
who had experienced both treatment modalities.
he choice of which route to use for Ig administration usually 
depends upon personal preference of the patient, ease of intra-
venous access, dose of Ig required, tolerability of any previous 
Ig products, patient lifestyle, and it can be reviewed regularly 
and adjusted throughout the period of treatment as patient’s 
circumstances change. However, it is worth mentioning that 
one study found IVIg treatment to be associated with higher 
levels of anxiety and depression. For example Heath et al. (42) 
speciically investigated anxiety and depression in adults with 
primary immunodeiciencies, and how their experiences of 
mental health relate to their illnesses. hey assessed depression 
as well as anxiety with the Hamilton-Depression (HAM-D) and 
Hamilton-Anxiety (HAM-A) questionnaires. heir participants 
included adults who had either received IV IG, either at home 
or hospital, and patients receiving home-SC. While this was not 
intended as a direct comparison of treatment burden for both 
groups, the authors report some relevant indings: in regards to 
depression, it was found that patients receiving IVIg (home or 
hospital) scored signiicantly higher on the HAM-D scale than 
SC patients, and thus were signiicantly more depressed than SC 
patients (p = 0.0004). he authors concluded that receiving IVIg 
treatment may, therefore, be a risk factor for PID patients for 
developing depression. For the HAM-A, the relevant inding to 
this review is that IVIg patients attributed higher percentages of 
their anxiety to their PID diagnoses compared to patients receiv-
ing SCIg (p = 0.030). Monitoring the psychological well-being of 
PID patients receiving IVIg therapy especially may, therefore, be 
needed although more research is warranted to investigate this 
possible relationship further.
he main limitation of the evidence identiied from this review 
is the lack of direct comparisons between patients who have 
only ever received one modality of treatment, which means that 
changes in outcomes like HRQoL or treatment burden could 
be due to factors other than changes in the treatment regimen. 
In addition, many of the included studies were performed by a 
relatively small group of authors with small sample sizes and it 
is likely that some of the same patients were included in multiple 
studies which would have the efect of exaggerating the quantity 
of evidence available, and would bias the results of this review 
signiicantly.
cONcLUSiON aND RecOmmeNDatiONS 
FOR FUtURe ReSeaRcH
his study presents a summary of the evidence concerning the 
perceived burden of Ig treatment from the patient’s perspec-
tive. Speciically, this review assessed relevant concepts, such as 
HRQoL, patient satisfaction, treatment preference, and subjective 
experiences of patients. hese are all aspects relevant to the BoT, 
but potentially also the burden of disease.
Overall, it appeared that PID patients reported little Ig treat-
ment burden. Ig therapy at home appears preferable to clinic-based 
treatment and SCIg at home was the most desirable treatment 
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modality. However, individual diferences do afect treatment pref-
erence and exploring and identifying the decision support needs of 
PID patients facing IG treatment choices would be valuable using 
a shared-decision making approach.
However, the heterogeneity of the disease speciic and generic 
outcome measures used to assess treatment burden in these 
studies, none of which directly assess the BoT, and the use of 
non-validated measures makes synthesizing the current evi-
dence concerning Ig treatment burden diicult. If HRQoL is the 
primary outcome of interest then a HRQoL instrument is most 
appropriate to use. However, if the intent is to measure BoT then 
such a measure should be selected. Indeed, a measure speciically 
designed to measure Ig treatment burden from the patient’s per-
spective may therefore be of value and one is currently in the early 
stages of development and testing (Jones et al., unpublished). 
Future research to explore how perceived adult IG treatment bur-
den may difer to children’s perceptions of Ig treatment burden 
would be recommended—especially as patients need to stay on 
Ig treatment for the duration of their lives and this information 
could be used to better support patients transitioning between 
pediatric and adult centers for treatment.
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